Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.57 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 5/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246378 | 0.90 | PARP10 (0.63) | MAPKAPK2RYR2PARP1PARP10F7 | |
| SCHEMBL29438649 | 0.90 | PARP10 (0.63) | MAPKAPK2RYR2PARP1PARP10F7 | |
| SCHEMBL3692167 | 0.88 | GRM5 (0.56) | MAPKAPK2RYR2KDRPARP1PARP10 | |
| SCHEMBL2849831 | 0.80 | PDE3B (0.53) | MAPKAPK2RYR2KDRACHEMETAP1 | |
| SCHEMBL31069587 | 0.80 | PDE3B (0.53) | MAPKAPK2RYR2KDRACHEMETAP1 | |
| SCHEMBL15830755 | 0.79 | PARP10 (0.81) | MAPKAPK2PARP1PARP10F7F3 | |
| SCHEMBL8323443 | 0.78 | GRM5 (0.67) | MAPKAPK2RYR2PARP1PARP10GRM5 | |
| SCHEMBL379341 | 0.78 | GRM5 (0.67) | MAPKAPK2RYR2PARP1PARP10GRM5 | |
| SCHEMBL120284 | 0.77 | MAOB (0.58) | NPY5RACHEMETAP1CYP19A1KDM4E | |
| SCHEMBL1395133 | 0.77 | HRH3 (0.52) | MAPKAPK2KDRPARP1CDK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-5674863-A | BENZODIAZEPINEDIONE DERIVATIVE; FIBRINOGIN BINDING INHIBITOR | GENENTECH, INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5674865-A | BENZODIAZEPINEDIONE DERIVATIVE; FIBRINOGIN BINDING INHIBITOR | GENENTECH, INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5663166-A | ANTICOAGULANTS OF 1,4-BENZODIAZEPINE-2,5-DIONE AND 2-BENZOAZEPINE-1,4-DIONE DERIVATIVES; PREVENTS FIBRINOGEN BINDING NECESSARY FOR PLATELET AGGREGATION; SIDE EFFECT REDUCTION, E.G. EXCESSIVE BLEEDING | GENENTECH, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5565449-A | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0610334-B1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII B III A RECEPTOR | GENENTECH INC (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5403836-A | Anticoagulants | GENENTECH, INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0610334-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII b?III a? RECEPTOR. | GENENTECH INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5250679-A | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor | GENENTECH, INC. (US) | 1993-10-05 | — | — | US | disclosed |
| WO-1993008174-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPIIbIIIa RECEPTOR | GENENTECH, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246433-B2 | Aryl and heteroaryl fused lactams | CCNY, MLX, NFXL1 | MAPKAPK2 4772/4885RYR2 4384/4885KDR 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.